U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07259018) titled 'LUMENS-1 CANADA EFS CIP' on Nov. 17.
Brief Summary: The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a single-arm, open-label, single-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 10 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled in a Canadian site.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Aneurysm Cerebra...